COMP <GO>
MDLN vs JNJ // FORWARD P/E MULTIPLE
Medline Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: MDLN 5
— JNJ 9
▲ FORWARD P/E MULTIPLE LEADER: MDLN
LAST: $32.12 (+0.38%) • MKT CAP: $42.07B
forward-pe
4.2x
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
forward-pe
23.0x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MDLN VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MDLN | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 26.40% | 67.90% | -41.50 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.20% | 25.50% | -17.30 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 20.3x | 18.5x | +1.80 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 3.08% | 2.97% | +0.11 | MDLN | /fcf-yield <GO> |
| Operating Margin | 7.80% | 34.70% | -26.90 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 28.50% | +39.50 | MDLN | /net-margins <GO> |
| Revenue Growth (YoY) | 11.50% | 6.00% | +5.50 | MDLN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.50 | 5.59 | -3.09 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.30% | 7.20% | +0.10 | JNJ | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 31.6 | 60.4 | -28.79 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.11 | 1.08 | +0.03 | MDLN | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 4.2x | 23.0x | -18.80 | MDLN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $42.07B | $662.49B | -$620.42B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MDLN REV | JNJ REV | MDLN GROSS % | JNJ GROSS % | MDLN FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $28.43B | $94.19B | 26.4% | 67.9% | $1.30B | $19.70B |
| FY 2024 | $25.51B | $88.82B | 27.3% | 69.1% | $1.42B | $19.84B |
| FY 2023 | $23.23B | $85.16B | 44.0% | 44.0% | $639.6M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MDLN // BETA 1.11
JNJ // BETA 1.08